# Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

> **NCT03490942** · PHASE2 · TERMINATED · sponsor: **Xeris Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Hypoglycemia Unawareness
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Glucagon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03490942
- **Lead sponsor:** Xeris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-15
- **Primary completion:** 2019-11-04
- **Final completion:** 2020-02-10
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Primary endpoint was not met
- **Last updated:** 2021-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490942, "Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03490942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*